Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
4basebio will supply clinical—grade opDNA starting material for a multi—national pharma client’s Phase I cell therapy program, with TriLink BioTechnologies selected as CDMO to manufacture the mRNA drug substance using CleanCap.Material DetailsContext by AI AnalystThis extends 4basebio’s push to rep…
CAMBRIDGE, UK — 28 September, 2026 — 4basebio PLC AIM:4BB, a specialist in enzymatically-produced DNA for new genetic medicines, announces they will supply clinical-grade opDNA® starting material for a multi-national pharmaceutical innovator’s (“the Client”) latest cell therapy program.Under the ag…
The company will supply clinical-grade opDNA starting material for a multinational pharmaceutical company’s Phase I cell therapy trial.